A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulation/IUI therapy.

Williams RS, Hillard JB, De Vane G, Yeko T, Kipersztok S, Rhoton-Vlasak A, Sistrom C

American journal of obstetrics and gynecology1 Aug 2004Cited by 29 (Europe PMC)

PMID15343256DOI10.1016/j.ajog.2004.06.072PepBankPUB-15343256

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women undergoing superovulation/IUI, clinical pregnancy rates were 12% with ganirelix versus 7% without ganirelix (P =.29).
In plain wordsIn women undergoing superovulation/IUI, pregnancy rates did not differ significantly with versus without ganirelix (12% versus 7%).
Peptide
Ganirelix
Outcome
No significant changeClinical pregnancy per cycle initiated
Study
n = 54
Comparator
rFSH superovulation/IUI without ganirelix
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Clinical pregnancy rate per cycle initiated
12%
ganirelix (treatment) group
Clinical pregnancy rate per cycle initiated
7%
control group without ganirelix
p value
0.29
between groups
Source sentences
Summary
No statistically significant difference in clinical pregnancy rates per cycle initiated was found for patients in the treatment or control group (12% vs 7%, P =.29).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, prospective, randomized, open-label, assessor-blind, controlled trial of females (n = 54), ages 18 to 39 undergoing superovulation/IUI with up to 4 cycles of superovulation/IUI without Ganirelix (n = 66), or up to 4 cycles of superovulation/IUI with the addition of Ganirelix (n = 52).
Report a problemFND-1534325601
02HumanRandomized controlled trialEfficacy outcome
In superovulation/IUI, endometrial thickness, follicle size, estradiol, mid-luteal progesterone and rFSH use did not differ significantly with versus without ganirelix.
In plain wordsIn superovulation/IUI, endometrial thickness, follicle size, estradiol, progesterone and rFSH use did not differ significantly with versus without ganirelix.
Peptide
Ganirelix
Outcome
No significant changeOther measured stimulation outcomes
Study
n = 54
Comparator
rFSH superovulation/IUI without ganirelix
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Other variables assessed, including endometrial thickness, size of follicles, peak serum estradiol levels, mid-lutea progesterone levels, and total vials of rFSH used also showed no statistically significant difference.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, prospective, randomized, open-label, assessor-blind, controlled trial of females (n = 54), ages 18 to 39 undergoing superovulation/IUI with up to 4 cycles of superovulation/IUI without Ganirelix (n = 66), or up to 4 cycles of superovulation/IUI with the addition of Ganirelix (n = 52).
Report a problemFND-1534325602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.